The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

The University of Kansas Cancer Center
A

2021 Updates on MF: Addition of Parsaclisib in Patients With Suboptimal Response to Ruxolitinib

By The University of Kansas Cancer Center FEATURING Abdulraheem Yacoub
By The University of Kansas Cancer Center FEATURING Abdulraheem Yacoub
47 views
May 19, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
Videos
12:21
Insights from 2023 SABCS

SABCS 2023 Insights: "How to Treat TNBC"

Feat. P. Sharma
09:24
The University of Kansas Cancer Center

Treatment Sequence in mTNBC

Feat. P. Sharma
07:47
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "The X-7/7 Randomized Trial - Fixed Dose C…

Feat. C. Bohnenkamp
14:05
The University of Kansas Cancer Center

Five-Year Updates on Venetoclax + Obinutuzumab for Previously Untrea…

Feat. M. Hoffmann
13:40
SABCS 2021 Conference Coverage on VuMedi

Optimizing Use of HER2 Therapies in MBC

Feat. P. Sharma
10:44
The University of Kansas Cancer Center

Phase II DREAMM-2: Belantamab Mafodotin in R/R MM

Feat. A. Abdallah
07:59
The University of Kansas Cancer Center

2021 ASCO Updates From LIMBER-313 on Myelofibrosis: Parsaclisib + Ru…

Feat. A. Yacoub
08:58
The University of Kansas Cancer Center

ASCO 2021 Update on mTNBC: Considering Outcomes With Romidepsin / Ci…

Feat. P. Sharma
11:45
The University of Kansas Cancer Center

2021 Updates on MF: Addition of Parsaclisib in Patients With Subopti…

Feat. A. Yacoub
06:08
The University of Kansas Cancer Center

2020 Update on PARPi/Chemo Option in mTNBC: How Effective Is the Add…

Feat. P. Sharma